Hot Features
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome prolifer... Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.515 | 15.8705701079 | 3.245 | 4.045 | 3.14 | 264106 | 3.32404615 | DE |
| 4 | 0.46 | 13.9393939394 | 3.3 | 4.045 | 2.88 | 297438 | 3.19228982 | DE |
| 12 | -0.83 | -18.082788671 | 4.59 | 5.05 | 2.88 | 382730 | 3.92700048 | DE |
| 26 | -0.54 | -12.5581395349 | 4.3 | 6.2 | 2.88 | 375052 | 4.56407173 | DE |
| 52 | 0.95 | 33.8078291815 | 2.81 | 6.2 | 2.785 | 369632 | 4.29698488 | DE |
| 156 | 0.03 | 0.804289544236 | 3.73 | 6.2 | 1.434 | 143437 | 4.02671777 | DE |
| 260 | -8.26 | -68.7188019967 | 12.02 | 13.18 | 1.434 | 105031 | 4.30768626 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.